Medication Safety Review in Early Pregnancy
Continue bupropion SR at current dose, engage in urgent shared decision-making regarding dextroamphetamine-amphetamine with strong consideration for either continuing at lowest effective dose with intermittent use or switching to bupropion monotherapy, and discuss risperidone continuation versus discontinuation based on severity of underlying psychiatric condition.
Dextroamphetamine-Amphetamine (Mixed Amphetamine Salts)
The 2024 American Journal of Obstetrics and Gynecology guidelines provide the most current framework for managing stimulants in pregnancy 1:
Key Recommendation: The consensus is that documented risks are very low and treatment should not be stopped if required for daily functioning 1. However, given this is early pregnancy with viability not yet established, you have a critical window for decision-making.
Risk Profile for Amphetamines:
- No association with major congenital malformations including cardiac defects 1
- Possible small increased risk for:
- These risks may be attributable to ADHD itself rather than medication 1
Management Options:
Option 1 (Preferred if ADHD severely impacts functioning):
- Continue dextroamphetamine-amphetamine at current 10 mg daily
- Consider intermittent/as-needed use to maximize functioning while reducing fetal exposure 1
- Monitor closely for preeclampsia (blood pressure checks), fetal growth, and appropriate maternal weight gain 1
Option 2 (If ADHD is moderate and patient has depressive symptoms):
- Switch to bupropion monotherapy (increase current 100 mg to therapeutic ADHD dose of 300-450 mg daily) 1
- Note: Bupropion is less efficacious than stimulants for ADHD but has established safety data in pregnancy 1
Option 3 (If ADHD unlikely to severely impact daily functioning):
- Trial of gradual discontinuation 1
Bupropion SR
Continue at current dose of 100 mg daily - this medication has the strongest safety profile in pregnancy among the current regimen.
Evidence:
- Bupropion has established safety data in the perinatal period 1
- Guidelines explicitly state to maintain therapeutic dose during pregnancy and breastfeeding 1
- No increased risk of major malformations demonstrated
- Current dose (100 mg) is subtherapeutic for both depression and ADHD; consider increasing to 150-300 mg daily for optimal psychiatric benefit, particularly if discontinuing amphetamine
Drug Interaction Consideration:
The FDA label notes bupropion inhibits CYP2D6 and can increase risperidone concentrations 3. If continuing risperidone, monitor for increased antipsychotic effects and consider dose reduction of risperidone if needed.
Risperidone
This requires the most careful risk-benefit analysis given mixed evidence and the patient's specific psychiatric indication (not provided in consult).
Risk Profile:
- Large Medicaid study (1.36 million pregnancies) found no meaningful increased risk for congenital malformations overall after confounding adjustment (RR 1.05,95% CI 0.96-1.16) 4
- However, risperidone specifically showed small increased risk for overall malformations (RR 1.26,95% CI 1.02-1.56) and cardiac malformations (RR 1.26,95% CI 0.88-1.81) that was independent of measured confounders 4
- This finding "requires additional study" per the research 4
Management Decision Tree:
If risperidone is treating:
- Psychosis/bipolar disorder with history of severe episodes: Continue at lowest effective dose (current 1 mg BID is relatively low). Risk of untreated severe mental illness outweighs small increased malformation risk.
- Mild mood symptoms or anxiety: Consider gradual taper and discontinuation, optimizing bupropion dose for mood support.
- Autism-related irritability: Reassess necessity during pregnancy; consider discontinuation if symptoms manageable without medication.
If continuing risperidone:
- Use lowest effective dose (may reduce from 1 mg BID to 0.5 mg BID if clinically appropriate)
- Arrange fetal echocardiography at 18-22 weeks given small cardiac malformation signal
- Monitor for metabolic effects (weight gain, glucose)
- Be aware of potential dose increase needed due to bupropion interaction 3
Melatonin
Continue as needed - minimal safety concerns. No human data suggest teratogenicity, though data are limited. The benefit for sleep (critical for psychiatric stability) likely outweighs theoretical risks.
Critical Monitoring Plan
- Serial hCG and early ultrasound (already planned) to establish viability
- Blood pressure monitoring throughout pregnancy (amphetamine-related preeclampsia risk)
- Fetal growth ultrasounds at 28,32,36 weeks if continuing stimulant
- Fetal echocardiography at 18-22 weeks if continuing risperidone
- Psychiatric follow-up every 2-4 weeks to assess medication efficacy and adjust as needed
Common Pitfalls to Avoid
- Do not reflexively discontinue all psychiatric medications - untreated ADHD is associated with spontaneous abortion and preterm birth 1
- Do not assume all antipsychotics carry equal risk - risperidone has a specific signal that differs from the class effect 4
- Do not underdose bupropion - 100 mg daily is subtherapeutic; if relying on this for mood/ADHD, increase to 150-300 mg
- Do not forget that pregnancy alters pharmacokinetics - some patients may need dose adjustments as pregnancy progresses, though bupropion shows minimal changes 5
Documentation for Shared Decision-Making
Document discussion of:
- Small absolute risks of continuing amphetamine (preeclampsia ~1.1% increased risk, preterm birth ~3% increased risk)
- Risks of untreated ADHD (functional impairment, driving safety, occupational dysfunction, pregnancy complications)
- Risperidone's specific small malformation signal versus severity of underlying psychiatric condition
- Patient's values and preferences regarding medication exposure versus psychiatric stability